European Medicines Agency– tag –
-
Vyjuvek Secures UK MHRA Approval; REGENXBIO’s RGX-202 Achieves Primary Endpoint in Duchenne Muscular Dystrophy Phase 3 Trial
YouTube (Lucid Quest) USA Overview A May 28, 2026, update reported that Vyjuvek, a gene therapy for dystrophic epidermolysis bullosa, has received UK MHRA approval. Concurrently, REGENXBIO's RGX-202, a gene therapy for Duchenne muscular ... -
EMA Initiates Review of Otarmeni’s Hereditary Hearing Loss Gene Therapy; Eli Lilly Announces Phase 2 Plans for VERVE-102 in Cardiovascular Disease
LucidQuest Ventures USA Overview Key developments in the cell and gene therapy sector were reported on May 28, 2026, with Otarmeni's hereditary hearing loss gene therapy entering EMA review. Eli Lilly detailed its Phase 2 clinical trial ... -
Vertex Pharmaceuticals Secures CASGEVY Reimbursement Agreement in Germany for Sickle Cell Disease and Beta Thalassemia
Vertex Pharmaceuticals USA Overview Vertex Pharmaceuticals announced a reimbursement agreement in Germany for CASGEVY (exa-cel), a groundbreaking gene-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassem... -
Pharmaceutical Membrane Filtration Market: Size, Share, and Growth Forecast to 2034 – A Straits Research Overview
Straits Research Germany Overview This article provides an overview of a market research report published by Straits Research, detailing the pharmaceutical membrane filtration market's current status and projected growth to 2034. The rep... -
FDA Finalizes Guidance on CMC Flexibility for Cell and Gene Therapies, Expediting Access to Advanced Treatments
Regulatory Focus USA Overview The U.S. FDA has issued final guidance outlining flexible Chemistry, Manufacturing, and Controls (CMC) requirements for cell and gene therapy (CGT) products, recognizing their inherent complexities compared ...
